TY - JOUR
T1 - Use of telephone helpline data for syndromic surveillance of adverse events following immunization in Australia
T2 - A retrospective study, 2009 to 2017
AU - Mesfin, Yonatan M.
AU - Cheng, Allen C.
AU - Enticott, Joanne
AU - Lawrie, Jock
AU - Buttery, Jim P.
PY - 2020/7/22
Y1 - 2020/7/22
N2 - Background: The increasing availability of electronic healthcare data offers an opportunity to enhance adverse events following immunisation (AEFI) signal monitoring in near real-time. Aim: To evaluate the potential use of telephone helpline data to augment the existing AEFI surveillance system in Victoria, Australia. Methods: Anonymised telephone helpline call data were extracted between 2009 and 2017. For comparison, we included AEFI reports to the Victorian enhanced passive surveillance system, SAEFVIC-“Surveillance of Adverse Events Following Vaccination In the Community”. The temporal pattern cross-correlation coefficient at different time lags was estimated as a measure of timeliness evaluation. Historically known AEFI signals in 2010 and 2015 were examined using the Farrington statistical signal detection algorithm. Result: During the study period, overall, the telephone helpline centre received 2,005,226 calls. Of these, 0.68% (13,719) were AEFI-related. In the same period, SAEFVIC received 10,367 AEFI related reports. Cross-correlation analysis, generally, showed that the two datasets were moderately correlated (r = 0.4) at a negative lag of 1 week. For individual years, the cross-correlation coefficient was highest (r = 0.66) in 2010 with the telephone helpline data leading by 2 weeks. Our analysis indicated the 2010 reported incidence of febrile convulsions and the 2015 reported increased allergic-related reactions following seasonal influenza vaccination three weeks and one week earlier respectively. Conclusion: Telephone helpline data was able to detect an increased rate of AEFI earlier than the enhanced passive AEFI surveillance system. This dataset offers a valuable and near real-time component of an integrated AEFI early signal detection system in Australia.
AB - Background: The increasing availability of electronic healthcare data offers an opportunity to enhance adverse events following immunisation (AEFI) signal monitoring in near real-time. Aim: To evaluate the potential use of telephone helpline data to augment the existing AEFI surveillance system in Victoria, Australia. Methods: Anonymised telephone helpline call data were extracted between 2009 and 2017. For comparison, we included AEFI reports to the Victorian enhanced passive surveillance system, SAEFVIC-“Surveillance of Adverse Events Following Vaccination In the Community”. The temporal pattern cross-correlation coefficient at different time lags was estimated as a measure of timeliness evaluation. Historically known AEFI signals in 2010 and 2015 were examined using the Farrington statistical signal detection algorithm. Result: During the study period, overall, the telephone helpline centre received 2,005,226 calls. Of these, 0.68% (13,719) were AEFI-related. In the same period, SAEFVIC received 10,367 AEFI related reports. Cross-correlation analysis, generally, showed that the two datasets were moderately correlated (r = 0.4) at a negative lag of 1 week. For individual years, the cross-correlation coefficient was highest (r = 0.66) in 2010 with the telephone helpline data leading by 2 weeks. Our analysis indicated the 2010 reported incidence of febrile convulsions and the 2015 reported increased allergic-related reactions following seasonal influenza vaccination three weeks and one week earlier respectively. Conclusion: Telephone helpline data was able to detect an increased rate of AEFI earlier than the enhanced passive AEFI surveillance system. This dataset offers a valuable and near real-time component of an integrated AEFI early signal detection system in Australia.
KW - Adverse events following immunization
KW - Safety signal detection
KW - Syndromic surveillance
KW - Telephone helpline data
UR - http://www.scopus.com/inward/record.url?scp=85086935493&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2020.05.078
DO - 10.1016/j.vaccine.2020.05.078
M3 - Article
AN - SCOPUS:85086935493
SN - 0264-410X
VL - 38
SP - 5525
EP - 5531
JO - Vaccine
JF - Vaccine
IS - 34
ER -